Barclays maintains Insulet at Equal-Weight, raises price target to $165 from $150
Barclays kept Insulet at Equal-Weight but raised its price target to $165 from $150, suggesting a 5.7% upside from the Nov 5 close of $156.12. Recent analyst notes on Insulet have price targets ranging from $167 to $180.
How this was made

The 30-second read
Why it matters
The upgrade may attract short‑term buying, pushing the stock closer to $165.
Market read
A fresh analyst target increase provides a modest trading catalyst for Insulet.
What to watch
Potential regulatory or reimbursement risks not reflected in the new target.
Background
Barclays' analyst note updates its valuation model for Insulet, reflecting recent market dynamics.
Market effects
Higher target may lift other diabetes device peers as the sector gains optimism.
U.S. market focus; limited regional spillover.
Modest; primarily affects Insulet and related med‑tech stocks.
Counterpoint
The target raise could be premature if upcoming earnings miss expectations.
Key entities
- AnalystBarclays
Equity research firm issuing the price target raise.
- CompanyInsulet
U.S.-listed medical device maker (ticker PINS).

